Amneal制药 AMRX 深 沪
等待开盘 02-07 09:30:00 美东时间
14.515
-0.255
-1.73%
华盛通- 最 高15.00
- 今 开14.89
- 成交量 231.56万股
- 最 低 12.3301
- 昨 收 14.77
- 总市值 219.18万
- 52周最高 15.00
- 市盈率 静 207.36
- 换手率 1533.49%
- 52周最低 0.00
- 委 比 21.67%
- 总股本 0.00亿
- 历史最高 15.00
- 量 比 0.93
- 振 幅 18.08%
- 历史最低 0.00
- 每 手 1
- 风险率 2.04%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Amneal Pharmaceuticals Gets FDA's Approval For Biologics Licensing Applications For Boncresa, Oziltus
Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (NASDAQ:AMRX) and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, today announced that the U.S. Food and Drug
2025-12-23 05:02
Amneal Pharmaceuticals Announces FDA's Approval For Albuterol Sulfate Inhalation Aerosol
Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's albuterol sulfate inhalation aerosol (90 mcg per
2025-12-02 21:09
Amneal Pharmaceuticals Announces U.S. FDA Approves Its Iohexol Injection
Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (NASDAQ:AMRX) today announced the U.S. Food and Drug Administration (FDA) has approved the Company's iohexol injection (300 mg Iodine/mL), the first generic
2025-11-14 05:03
Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension
Amneal Pharmaceuticals获FDA批准其1%泼尼松龙乙酸酯眼用悬液，计划于2025年第三季度上市。该药物用于治疗 steroid-responsive ocular inflammation， IQVIA数据显示2025年销售额约为2.01亿美元。
2025-06-12 12:00
Amneal to Participate at Upcoming Investor Conferences in June
Amneal Pharmaceuticals will participate in the Jefferies Global Healthcare Conference on June 5 and Goldman Sachs Global Healthcare Conference on June 10, with executives presenting and a live webcast available.
2025-05-29 20:05
Amneal Pharmaceuticals盘中异动 急速拉升5.02%报8.69美元
北京时间2024年12月03日03时02分，Amneal Pharmaceuticals, Inc.（AMRX.us）股票出现异动，股价大幅上涨5.02%。截至发稿，该股报8.69美元/股，成交量126.784万股，换手率0.41%，振幅5.80%。 最近的财报数据显示，该股实现营业收入7.02亿美元，净利润-156000.00美元，每股收益0.00美元，毛利2.70亿美元，市盈率-10.09倍。 机构评级方面，在所有4家参与评级的机构中，75%的券商给予买入建议，25%的券商给予持有建议，无券商给予卖出建议。 Amneal Pharmaceuticals, Inc.股票所在的制药行业中，整体...
2024-12-03 03:02
Amneal Launches CREXONT Extended-Release Capsules For Treatment Of Parkinson's Disease
CREXONT now available in U.S. pharmacies nationwideComprehensive access and affordability services to be made available to Parkinson's patients and healthcare providersAmneal to hold CREXONT launch symposium and
2024-09-23 20:00
JP Morgan Upgrades Amneal Pharmaceuticals to Neutral, Announces $9 Price Target
JP Morgan analyst Chris Schott upgrades Amneal Pharmaceuticals (NASDAQ:AMRX) from Underweight to Neutral and announces $9 price target.
2024-09-06 20:10
Amneal Pharmaceuticals Says US FDA Approves Generic Drug Application for Propofol
08:32 AM EDT, 08/20/2024 (MT Newswires) -- Amneal Pharmaceuticals (AMRX) said Tuesday that its abbreviated new drug application for the single-dose formulation of anesthetic propofol has gained approval from the US Food and Drug Administration. The company said it expects to launch propofol in Q4. S...
2024-08-20 20:32
Amneal Expects 2024 Revenues Of $2.70B-$2.80B Versus Prior Guidance Of $2.55B-$2.65B And Consensus Of $2.646B
Raising Full Year 2024 Guidance The Company is raising its previously provided full year 2024 guidance. Updated Guidance Prior Guidance Net revenue $2.70 billion - $2.80 billion $2.55 billion - $2.65 billion Adjusted EBITDA (1) $610 million - $630 million $580 million - $620 million Adjusted dilut...
2024-08-09 18:09
